FOR PREVIEW ONLY (Print)

Dermot P. McGovern, MD, PhD

Joshua L. and Lisa Z. Greer Chair in Inflammatory Bowel Disease Genetics

Professor, Medicine and Biomedical Sciences

Director, Translational Research in the Inflammatory Bowel and Immunobiology Research Institute

Thalians Health Center
8730 Alden Drive
Los Angeles, CA 90048

Phone:

310-423-4100

Fax:

310-423-1486

Dermot P. McGovern, MD, PhD

Joshua L. and Lisa Z. Greer Chair in Inflammatory Bowel Disease Genetics

Professor, Medicine and Biomedical Sciences

Director, Translational Research in the Inflammatory Bowel and Immunobiology Research Institute

  • IM/Gastroenterology
  • Inflammatory Bowel Disease

Crohn's Disease

Inflammatory Bowel Disease (IBD)

Ulcerative Colitis

Dermot McGovern completed his GI fellowship and obtained a PhD in complex disease genetics at the University of Oxford, England before moving to Cedars-Sinai, Los Angeles 11 years ago. Dr McGovern is the Director of Translational Medicine at the F. Widjaja Foundation Imflammatory Bowel and Immunobiology Research Institute at Cedars-Sinai and also directs the Cedars-Sinai Precision Medicine Initiative. He holds the Joshua and Lisa Greer Endowed Chair in IBD Genetics. Dr. McGovern’s clinical interests include the extra-intestinal complications of IBD and also the overlap between IBD and other immune-mediated and metabolic diseases. Dr. McGovern serves on the National Scientific Advisory Committee for the Crohn’s and Colitis Foundation as well as the steering committees of the National and International IBD Genetics Consortia. He also chairs the CCFA local advisory medical committee. Dr. McGovern serves on the editorial board for the IBD Journal. He has been elected a member of the American Society for Clinical Investigation (ASCI) and also the International Organization for the Study of IBD (IOIBD). Dr. McGovern’s group is funded by the NIH to study the effect of genetics on the susceptibility to and natural history of IBD in diverse populations. Dr McGovern’s group analyze multi’-omic’ datasets to identify potential biomarkers and therapeutic targets of IBD that ‘feed’ the Drug Development Unit he co-directs. His group also have a significant interest in the pharmacogenetics of therapies used in IBD. Extending these studies to diverse populations including African-Americans, Hispanics, and the Ashkenazi Jewish population is a major focus of his group. His group is also funded by the Crohn’s and Colitis Foundation, The Litwin Foundation, and the Helmsley Charitable Trust. Dr. McGovern’s group have published approximately 150 peer-reviewed papers in journals including Nature, Science, Cell, Nature Genetics, The Lancet, and Gastroenterology.

  • Medical School: St Mary's Hospital Medical School, 1993
  • Internship: Gloucestershire Royal Hospital, 1994
  • Residency: Gloucestershire Royal Hospital, 1996
  • Fellowship: Royal Cornwall Hospital, 1999
  • Fellowship: South West Peninsula Deanery, 2000
  • Doctorate: Oxford Deanery, 2005
  • Fellowship: Oxford Deanery, UK, 2006

View CV as a PDF

  • Joshua L. and Lisa Z. Greer Chair, Inflammatory Bowel Disease Genetics, 2011
  • Fellow, The Royal College of Physicians of London, 2011
  • Editorial Board: Journal of Crohns and Colitis, 2007-11
  • Editorial Board: IBD Journal, 2008-10
  • American Gastroenterology Association, 2008
  • EPA Cephalosporin Junior Research Fellowship, 2002-04
  • British Society of Gastroenterology, 1997
  • The Royal College of Physicians of London, 1995

Show moreShow less

Click here for a list of peer-reviewed publications.

  • Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012 Nov 1;491(7422):119-24. doi: 10.1038/nature11582. PMID: 23128233, PMCID: PMC3491803 .
  • Exome Aggregation Consortium. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016 Aug 17;536(7616):285-91. doi: 10.1038/nature19057. PMID: 27535533, PMCID: PMC5018207
  • Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet. 2016 Jan 9;387(10014):156-67. doi: 10.1016/S0140-6736(15)00465-1. PMID: 26490195, PMCID: PMC4714968
  • Characterization of Genetic Loci That Affect Susceptibility to Inflammatory Bowel Diseases in African Americans. Gastroenterology. 2015 Nov;149(6):1575-86. doi: 10.1053/j.gastro.2015.07.065. PMID: 26278503, PMCID: PMC4685036 .
  • A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014 Sep;46(9):1017-20. doi: 10.1038/ng.3060. PMID: 25108385, PMCID: PMC4999337.

Show moreShow less

English

Make an Appointment

Call

1-800-CEDARS-1

(1-800-233-2771)

Available 24 Hours A Day

or

Many of the physicians who have medical staff privileges to practice medicine at Cedars-Sinai Medical Center are independent physicians, and not employees or agents of the hospital. These independent physicians bill separately for their services. You should contact your physician to determine their status and billing practices.

Send Email to Dermot P. McGovern, MD, PhD